当地时间2024年9月13日-17日，备受关注的2024欧洲肿瘤内科学会（ESMO）年会将于在西班牙巴塞罗那盛大召开。ESMO大会将一如既往为肿瘤领域带来最新前沿进展与诊疗理念，为改变临床实践、探索研究风向等提供学术交流平台。当前，ESMO官网公布了入选本届年会的摘要标题，【肿瘤资讯】整理了消化道肿瘤领域的优选口头报告（Proffered Paper session）和迷你口头报告（Mini Oral session）部分（LBA标题尚未公布），带您前瞻重磅进展！
Proffered Paper session2：上消化道肿瘤
摘要号：1400O
英文标题：Final overall survival for the phase 3, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma
中文标题：III期KEYNOTE-811研究最终总生存结果：帕博利珠单抗联合曲妥珠单抗和化疗治疗HER2阳性晚期、不可切除或转移性G/GEJ腺癌
讲者：Yelena Y. Janjigian (New York, United States of America, NY)
摘要号：1401O
英文标题：Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)
中文标题：德曲妥珠单抗（T-DXd）单药治疗和联合治疗晚期/转移性HER2阳性（HER2+）食管、胃或胃食管交界处腺癌（GEJA）患者:DESTINY-Gastric03（DG-03）
讲者：Yelena Y. Janjigian (New York, United States of America, NY)
Mini Oral session：上消化道肿瘤
摘要号：1402MO
英文标题：An international study evaluating pathological response to guide adjuvant FLOT chemotherapy in gastroesophageal cancer
中文标题：一项评估胃食管癌病理反应以指导FLOT辅助化疗的国际研究
讲者：Margaret M. Lee (Box Hill, Australia)
摘要号：1504MO
英文标题：Phase 2 Trial of Pembrolizumab and OLApaRib (POLAR) Maintenance for Select Patients (pts) with Metastatic Pancreatic Cancer (mPC) with (A) Homologous Recombination Deficiency (HRD), (B) non-core HRD (ncHRD) and (C) Exceptional Response to Platinum
中文标题：一项2期试验：帕博利珠单抗和奥拉帕利（POLAR）维持治疗转移性胰腺癌（mPC）患者：（A）同源重组缺陷（HRD），（B）非核心HRD（ncHRD）和（C）对铂类的特殊反应
讲者：Wungki Park (New York, United States of America)
Proffered Paper session1：下消化道肿瘤
摘要号：502O
英文标题：Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: preliminary results of FFCD 1703 POCHI trial
中文标题：帕博利珠单抗联合CAPOX和贝伐珠单抗治疗微卫星稳定转移性结直肠癌和高免疫浸润患者：FFCD 1703 POCHI试验的初步结果
讲者：David Tougeron (Poitiers, France, CEDEX)
摘要号：503O
英文标题：Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study.
中文标题：新辅助纳武利尤单抗（nivo）联合 relatlimab（rela）治疗dMMR结肠癌:NICHE-3研究结果
讲者：Peter G. De Gooyer (Amsterdam, Netherlands)
摘要号：504O
英文标题：IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors: results of the colorectal cancer cohort
中文标题：新辅助帕博利珠单抗治疗dMMR/MSI肿瘤的II期IMHOTEP试验：结直肠癌队列结果
讲者：Christelle De la Fouchardiere (Marseille, Cedex 09, France, CEDEX)
Proffered Paper session2：下消化道肿瘤
摘要号：505O
英文标题：Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase 1b CodeBreaK 101 study
中文标题：Sotorasib（soto）、帕尼单抗（pani）和FOLFIRI一线（1L）治疗KRAS G12C突变转移性结直肠癌（mCRC）：来自1b期CodeBreaK 101研究的安全性和有效性分析
讲者：Salvatore Siena (Milan, Italy)
摘要号：506O
英文标题：Evaluation of risk of disease progression in first-line therapy of unresected metastatic colorectal cancer to guide intervals of radiological assessment- an analysis of eleven randomized trials by AIO and GONO
中文标题：评价不可切除转移性结直肠癌一线治疗的疾病进展风险以指导放射学评估间隔- AIO和GONO对11项随机试验的分析
讲者：Marco M. Germani (Pisa, Italy)
Mini Oral session：下消化道肿瘤
摘要号：507MO
英文标题：Impact of lean body mass-based oxaliplatin dosage on neurotoxicity in adjuvant treatment of stage III colorectal cancer. Final results of the phase II randomized multicenter LEANOX trial
中文标题：基于瘦体重的奥沙利铂剂量对III期结直肠癌辅助治疗中神经毒性的影响：II期随机多中心LEANOX试验的最终结果
讲者：Eric Assenat (Montpellier, Cedex 5, France, CEDEX 5)
摘要号：508MO
英文标题：Organ preservation in early rectal adenocarcinoma: 5-year results of the randomized opera trial
中文标题：早期直肠腺癌的器官保留：随机OPERA试验的5年结果
讲者：Syrine Ben Dhia (Sousse, Tunisia)
摘要号：509MO
英文标题：Total Neoadjuvant Treatment (TNT) with Non-Operative Management (NOM) for Proficient Mismatch Repair Locally Advanced Rectal Cancer (pMMR LARC): First Results of NO-CUT Trial
中文标题：非手术管理（NOM）的全程新辅助治疗（TNT）治疗错配修复正常局部晚期直肠癌（pMMR LARC）: NO-CUT试验首次结果
讲者：Alessio Amatu (Milan, Italy)
摘要号：510MO
英文标题：Long-Term Survival and Organ Preservation with Pembrolizumab in Localized MSI-H/dMMR Solid Tumors
中文标题：帕博利珠单抗在局部MSI-H/dMMR实体瘤中的长期生存和器官保留
讲者：Kaysia Ludford (Houston, United States of America)
摘要号：511MO
英文标题：Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: the randomized phase II CITRIC trial.
中文标题：西妥昔单抗（Cet）和伊立替康在循环肿瘤DNA（ctDNA）选择的转移性结直肠癌（mCRC）患者中的三线治疗再挑战：随机II期CITRIC试验
讲者：Cristina Santos Vivas (L'Hospitalet de Llobregat, Spain)
摘要号：512MO
英文标题：Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients – The Phase III, Prospective-Randomized Placebo-Controlled Multicenter SAKK 41/13 Trial
中文标题：PIK3CA突变结肠癌患者的阿司匹林辅助治疗- III期前瞻性随机安慰剂对照多中心SAKK 41/13试验
讲者：Ulrich Güller (Thun, Switzerland)
摘要号：513MO
英文标题：Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase 1b/2 study
中文标题：Amivantamab联合FOLFOX或FOLFIRI治疗转移性结直肠癌：一项开放标签、1b/2期研究OrigAMI-1结果
讲者：Filippo Pietrantonio (Milan, Italy)
排版编辑：肿瘤资讯-AS
苏公网安备 32059002004080号
